Drugs.com Clinical Trial ResultsOriginal article
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase 2positiveTulisokibartPositive
AI Analysis
Summary
Merck announced positive Phase 2b results for tulisokibart (MK-7240) in hidradenitis suppurativa, meeting primary and key secondary endpoints in the MK-7240-012 study.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Met primary and key secondary endpoints in Phase 2b study
Importance:7/10
Sentiment:
0.85
Phase_2bHidradenitis_SuppurativaData_ReadoutDermatology
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 30, 2026 11:09 PM